We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-6.35%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$11.4B
AUM Growth
-$782M
Cap. Flow
+$157M
Cap. Flow %
1.38%
Top 10 Hldgs %
87.68%
Holding
124
New
6
Increased
21
Reduced
9
Closed
4

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$234M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$100M
3
ASND icon
Ascendis Pharma A/S
ASND
+$10.6M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$9.37M
5
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$6.88M

Top Sells

Rank Stock Value
1
ACOR
Acorda Therapeutics
ACOR
+$69.3M
2
DERM
Dermira, Inc.
DERM
+$14.2M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$13.5M
4
EXEL icon
Exelixis
EXEL
+$11M
5
CERS icon
Cerus
CERS
+$9M

Sector Composition

Rank Sector Weight
1 Healthcare 92.56%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INCY icon
1
Incyte
INCY
$25.2B
$4.3B 37.57%
34,130,161
+20,150
+0.1% +$2.56M
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
$2.37B 20.68%
45,725,556
+10,000
+0% +$636K
ALXN
3
DELISTED
Alexion Pharmaceuticals
ALXN
$1.04B 9.1%
8,553,864
+2,009,734
+31% +$234M
ACAD icon
4
Acadia Pharmaceuticals
ACAD
$4.46B
$720M 6.3%
25,819,768
– –
BMRN icon
5
BioMarin Pharmaceuticals
BMRN
$11.9B
$536M 4.69%
5,905,673
+1,099,190
+23% +$100M
GHDX
6
DELISTED
Genomic Health, Inc.
GHDX
$449M 3.92%
13,779,866
+8,884
+0.1% +$281K
DBVT
7
DBV Technologies
DBVT
$799M
$197M 1.72%
550,956
– –
ONC
8
BeOne Medicines Ltd
ONC
$33.9B
$165M 1.45%
3,673,175
– –
NGNE icon
9
Neurogene
NGNE
$648M
$154M 1.35%
546,708
– –
AKAO
10
DELISTED
Achaogen Inc
AKAO
$104M 0.91%
4,804,604
+222,222
+5% +$5.07M
AMRN
11
Amarin Corp
AMRN
$300M
$91.4M 0.8%
1,133,475
+652
+0.1% +$40.5K
AAAP
12
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$86.7M 0.76%
2,221,706
– –
ONCE
13
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$78.8M 0.69%
1,318,341
– –
NVTA
14
DELISTED
Invitae Corporation
NVTA
$69.7M 0.61%
7,288,300
– –
BCRX icon
15
BioCryst Pharmaceuticals
BCRX
$2.44B
$65.1M 0.57%
11,716,784
– –
BLCM
16
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$58.8M 0.51%
503,231
– –
AVXS
17
DELISTED
AveXis, Inc. Common Stock
AVXS
$51.4M 0.45%
625,000
+125,000
+25% +$9.37M
EXEL icon
18
Exelixis
EXEL
$14B
$51.3M 0.45%
2,082,012
-521,557
-20% -$11M
ASND icon
19
Ascendis Pharma A/S
ASND
$16.5B
$48.6M 0.43%
1,751,463
+400,000
+30% +$10.6M
HRTX icon
20
Heron Therapeutics
HRTX
$92.5M
$38.6M 0.34%
2,783,569
– –
SGMO
21
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$36.2M 0.32%
4,113,376
-417,525
-9% -$2.68M
BLUE
22
DELISTED
bluebird bio
BLUE
$31.7M 0.28%
23,271
-3,860
-14% -$4.66M
ARAV
23
DELISTED
Aravive, Inc. Common Stock
ARAV
$29M 0.25%
276,766
– –
NBIX icon
24
Neurocrine Biosciences
NBIX
$18.2B
$28.4M 0.25%
616,682
-278,740
-31% -$13.5M
CERS icon
25
Cerus
CERS
$571M
$25.7M 0.22%
10,241,943
-2,811,332
-22% -$9M
1
2 3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2017 Portfolio in Review

As of Q2 2017, Baker Bros. Advisors held 124 positions worth $11.4B, down 6.4% from $12.2B the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Baker Bros. Advisors's Q2 2017 filing shows 6 new, 21 increased, 9 reduced and 4 closed positions. Its largest new stake was Lumos Pharma, Inc. Common Stock: 55,556 shares worth $3.67M. The largest sale was Acorda Therapeutics, an estimated $69.3M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier, followed by Technology.

  • Baker Bros. Advisors's largest Q2 2017 buy was Lumos Pharma, Inc. Common Stock: 55,556 shares worth $3.67M.
  • Baker Bros. Advisors added most to Alexion Pharmaceuticals in Q2 2017, an estimated $234M increase.
  • Baker Bros. Advisors's biggest Q2 2017 reduction was Neurocrine Biosciences, cutting an estimated $13.5M.
  • Baker Bros. Advisors fully exited Acorda Therapeutics in Q2 2017, selling an estimated $69.3M.
  • Baker Bros. Advisors's ten largest holdings make up 88% of its $11.4B portfolio in Q2 2017.
  • Baker Bros. Advisors opened 6 new positions and closed 4 in Q2 2017.
  • Baker Bros. Advisors's portfolio value fell 6.4% quarter-over-quarter to $11.4B.

Based on Baker Bros. Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.